Quantcast
Last updated on April 20, 2014 at 21:20 EDT

Latest cancer therapies Stories

2008-11-03 18:00:20

TORONTO, Nov. 3 /PRNewswire-FirstCall/ -- Bradmer Pharmaceuticals Inc., a biopharmaceutical company dedicated to the development and commercialization of cancer therapies, announced today that Dr. Alan M. Ezrin, President and Chief Executive Officer of the Company, will present a corporate update at Rodman & Renshaw 10th Annual Healthcare Conference, which is being held in New York City from November 10th - 12th at the New York Palace Hotel. Dr. Ezrin will provide an update on the...

2008-10-23 06:00:11

DUBLIN, Calif., Oct. 23 /PRNewswire-FirstCall/ -- SuperGen, Inc. , a pharmaceutical company dedicated to the discovery and development of novel cancer therapies, today presented data on MP-470, its lead product candidate, and four additional posters, at the 20th EORTC-NCI-AACR Symposium on "Molecular Targets and Cancer Therapeutics" in Geneva, Switzerland. MP-470, an orally bio-available multi-targeted tyrosine kinase inhibitor, showed encouraging tumor regression results in the first two...

2008-10-14 09:00:45

WALTHAM, Mass., Oct. 14 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, of the many targeted cancer agents in Phase III clinical trials in the adjuvant setting, surveyed oncologists say that Genentech/Roche/Chugai's Avastin in early-stage colorectal cancer holds the most promise to achieve regulatory approval. Additionally, more than half of surveyed oncologists indicated that the minimum benefit...

2008-10-03 09:00:38

Targeted therapies have improved treatment outcomes in cancer notably, becoming the leading therapy class in the oncology market. As a result, they are expected to achieve sales of over $42 billion by 2017. Eight more marketed brands are set to achieve blockbuster status over the 10-year forecast period, driven by the persistent unmet need that still exists across a number of tumor types. In 1997, Biogen Idec/Genentech/Roche/Zenyaku Kogyo's Rituxan (rituximab) - a monoclonal antibody used...

2008-09-30 09:00:18

TORONTO, Sept. 30 /PRNewswire-FirstCall/ -- Bradmer Pharmaceuticals Inc. (TSX: BMR), a biopharmaceutical company dedicated to the development and commercialization of cancer therapies, today announced changes to its Board of Directors. Dr.ӚÓš EdӚÓš Miller, the Dean and Chief Executive Officer of Johns Hopkins University School of...

2008-08-11 09:01:40

TORONTO, Aug. 11 /PRNewswire-FirstCall/ -- Bradmer Pharmaceuticals Inc., a clinical oncology company specializing in the development and commercialization of cancer therapies, today announced its 2008 second quarter operational and financial results. Operational Highlights During the three months ended June 30, 2008 and the period subsequent to this date, the Company achieved the following milestones: - Submitted and received approval from the Food and Drug Administration...

2008-08-08 09:00:28

The UK's cost-effectiveness watchdog NICE has delivered another blow to the developers of targeted cancer therapies by recommending against the use of four new kidney cancer drugs in the UK. This recommendation suggests that NICE is likely to look unfavorably on a number of other targeted therapies in development, severely limiting future growth of the targeted cancer therapies market in the UK. In its preliminary guidance report on a number of new targeted cancer therapies, the UK's...

2008-07-23 09:00:21

TORONTO, July 23 /PRNewswire-FirstCall/ -- July 23, 2008 - Bradmer Pharmaceuticals Inc. (TSX: BMR), a biopharmaceutical company dedicated to the development and commercialization of cancer therapies, today announced that it has initiated enrollment in the Phase III GLASS-ART Trial evaluating Neuradiab(TM), a monoclonal antibody conjugated to Iodine-131, as a front-line therapy for primary glioblastoma multiforme (GBM). The first patient was enrolled at the Preston Robert Tisch Brain Tumor...

2008-07-22 09:00:21

OncoVista Innovative Therapies, Inc. (OTC BB: OVIT.OB), a biopharmaceutical company engaged in the development and commercialization of targeted cancer therapies and diagnostics, announced today that patient recruitment has commenced in the company's Phase I/II study of cordycepin for the treatment of patients with terminal deoxynucleotidyl transferase (TdT)-positive refractory leukemia. Participating clinical sites include the Dana Farber Cancer Institute (Boston, MA) and the Cancer Therapy...

2008-07-17 09:00:19

TORONTO, July 17 /PRNewswire-FirstCall/ -- Bradmer Pharmaceuticals Inc. (TSX: BMR), a biopharmaceutical company dedicated to the development and commercialization of cancer therapies, today released progression free survival (PFS) data from two previously conducted Phase II trials of Neuradiab(TM) in glioblastoma multiforme (GBM) patients. As an exploratory endpoint of the single arm PhaseӚÓš II trials, the data...